43 results
8-K
IMPLQ
Impel Pharmaceuticals Inc
20 Dec 23
Impel Pharmaceuticals Announces Filing Voluntary Chapter 11 Cases and Signing of “Stalking Horse” Agreement to Facilitate Sale
6:08am
and restructuring strategy, the management of critical relationships and retention of experts, and such other duties as may be necessary or advisable in the course
424B5
IMPLQ
Impel Pharmaceuticals Inc
5 Oct 23
Prospectus supplement for primary offering
5:19pm
result in superior clinical outcomes. Our strategy is to pair our proprietary Precision Olfactory Delivery, or POD, upper nasal delivery technology … of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy.
We
8-K
EX-10.1
IMPLQ
Impel Pharmaceuticals Inc
4 Oct 23
Entry into a Material Definitive Agreement
5:21pm
@sullcrom.com
[Signature Page to Third Amendment]
OAKTREE-FORREST MULTI-STRATEGY, LLC
By: Oaktree Capital Management, L.P.
Its: Manager
By: /s
8-K
EX-99.1
IMPLQ
Impel Pharmaceuticals Inc
18 Sep 23
Regulation FD Disclosure
9:53pm
applicability First Product – Trudhesa®, first cycle approval in September 2021, launched October 2021 Go To Market Thesis: Our initial focused launch strategy …
Trudhesa Commercialization Strategy and Performance Update 12
Trudhesa – Q1 and YTD 2023 Performance Summary Migraine market continues robust growth
8-K
EX-10.1
gn8qsf hp
7 Sep 23
Entry into a Material Definitive Agreement
4:19pm
8-K
EX-10.1
hnvxqs 9d39cmi5
21 Aug 23
Entry into a Material Definitive Agreement
8:33am
8-K
EX-99.1
99o0uhcr20 sbk8gro
12 May 23
Impel Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update
8:03am
PRE 14A
tahkg3214b36
14 Apr 23
Preliminary proxy
4:11pm
8-K
EX-99.1
ub7unrkx
14 Nov 22
Impel PHARMACEUTICALS Announces THIRD Quarter 2022 Financial Results and Provides CORPORATE Update
7:55am
8-K
EX-99.1
tjv8tohlqkmm926je
15 Aug 22
Impel PHARMACEUTICALS Announces SECOND Quarter 2022 Financial Results and Provides CORPORATE Update
8:06am
424B5
fqr98yyuqzzpd0phk6r
24 May 22
Prospectus supplement for primary offering
4:32pm
S-3
y5qbg7l ziba
16 May 22
Shelf registration
4:49pm
8-K
EX-99.1
5fny42lou8 1pgbx5d
16 May 22
Impel PHARMACEUTICALS Announces first Quarter 2022 Financial Results and Provides CORPORATE Update
8:23am